- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review. (Pubmed Central) - Nov 19, 2024
First-line therapy is supportive care, although patients with severe mpox infection may be treated with advanced therapeutics. Mpox vaccination is effective and, if available, should be offered to individuals at risk of exposure to mpox.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal, Metastases: Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat. (Pubmed Central) - Nov 14, 2024
Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox. Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.
- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, Vistide (cidofovir) / Gilead
Journal: Treatment Efficacy of Cidofovir and Brincidofovir against Clade II Monkeypox Virus isolates. (Pubmed Central) - Nov 13, 2024
Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months. While there are no antiviral drugs currently approved to treat mpox specifically, the use of tecovirimat (TPOXX
- |||||||||| ACAM2000 (smallpox (vaccinia) live vaccine) / Emergent Biosolutions, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: Mpox-diagnosis, treatment, immunization, and prognosis (Pubmed Central) - Nov 6, 2024
Prognosis depends on the clade, the access to medical care, and the underlying health status. Immunocompromised persons and children are at a higher risk of a severe course.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Mpox (Monkeypox) Infection with Lymphocytic Infiltration of Eccrine Ducts (Grand Ballroom Salon II-III, 7th Floor; In-Person) - Nov 4, 2024 - Abstract #ASDP2024ASDP_127;
The pathology lacked the more developed findings of marked epidermal necrosis and viral cytopathic changes described in Mpox histopathology. We report this case to raise awareness that adnexal inflammation, including involvement of the eccrine ducts, may be an early pathologic finding and a clue to the diagnosis of Mpox in early lesions.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Clinical, epidemiological and molecular aspects of patients with mpox in Romania. (Pubmed Central) - Nov 4, 2024
Intra-host evolution was observed and documented in one patient with HIV-1 infection with uncontrolled viremia, showing slightly different mutation profiles in two body compartments. This study showed that the mpox cases from Romania presented similar clinical, epidemiological and mutational features with those reported by other European countries.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Ocular Complications of Mpox: Evolving Understanding and Future Directions. (Pubmed Central) - Oct 31, 2024
Treatment involves both systemic and topical therapies, with tecovirimat being the primary systemic option, though its efficacy and ophthalmic bioavailability remain under investigation. Ongoing surveillance and research are essential to further understand the epidemiology and ophthalmic features of mpox and, ultimately, to optimize prevention and treatment strategies for patients.
- |||||||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
One?year review of mpox in Hong Kong () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_508;
Screening for HIV in those presenting with mpox infection is crucial. It is also imperative to sustain efforts to enhance vaccination coverage among vulnerable groups.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France. (Pubmed Central) - Oct 24, 2024
We report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm3, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Severe mpox in an immunocompromised patient complicated by deep tissue infection: A case report. (Pubmed Central) - Oct 24, 2024
Our data provide evidence that Tecovirimat treatment selects for compartimentalized viral mutations (A288P). While the patient clinically benefited from repeated tecovirimat course, emergence of viral muations and deep tissue infection emphasizes the challenge and importance of infectious disease monitoring in mpox patient management.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: Severe Presentation of Mpox With Skin, Lung and Pleural Involvement in a Non-HIV Infected Kidney Transplant Recipient. (Pubmed Central) - Oct 23, 2024
Notwithstanding the initiation of early treatment with tecovirimat, a satisfactory response was not achieved until a reduction in immunosuppression to everolimus monotherapy, coupled with the transition to cidofovir for antiviral treatment. In conclusion, mpox has the potential to produce a severe form of systemic infection in individuals who have undergone solid organ transplantation, demanding a meticulous approach involving sequential antiviral treatment and modifications to immunosuppressive regimens in order to achieve complete healing.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era. (Pubmed Central) - Oct 21, 2024
Recent outbreaks have prompted the development of new diagnostic methods and treatments, including antivirals like Tecovirimat and vaccines such as MVA-BN...The global response to the Mpox resurgence requires integrated strategies combining vaccination, antiviral treatments, and public health policies tailored to high-risk populations. Future efforts should focus on vaccine distribution equity and enhancing diagnostic capabilities to effectively manage and mitigate the impact of Mpox.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Mechanisms of Tecovirimat Antiviral Activity and Poxvirus Resistance. (Pubmed Central) - Oct 14, 2024
F13 escape mutations in MPXV clinical isolates are at the dimer interface and prevent drug-induced dimerization in solution and cells. These findings, which decipher tecovirimat's mode of action, will allow better monitoring of poxvirus outbreaks and pave the way for developing more potent and resilient therapeutics.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Outbreak of monkeypox in Benidorm, Alicante (Spain) (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1283;
The outbreak was controlled before the routine availability of mpox vaccine programs and antivirals like tecovirimat. The infection control program and the information on preventive measures for people at risk were important factors in controlling the outbreak.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024. (Pubmed Central) - Oct 10, 2024
A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.
- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: Therapeutic agents for the treatment of human mpox. (Pubmed Central) - Oct 9, 2024
The large number of human cases has allowed retrospective observational study of these agents and facilitated recruitment in prospective trials. The ongoing evolution of the virus may pose challenges for therapeutic interventions, necessitating rigorous randomized controlled trials to guide clinical use.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Trial completion date, Trial primary completion date: UNITY: Assessment of the Efficacy and Safety of Tecovirimat in Patients with Monkeypox Virus Disease (clinicaltrials.gov) - Oct 8, 2024
P3, N=150, Recruiting,
The ongoing evolution of the virus may pose challenges for therapeutic interventions, necessitating rigorous randomized controlled trials to guide clinical use. Trial completion date: Jan 2025 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Mar 2025
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
NATURAL KILLER LYMPHOCYTOPENIA IN A CASE OF NECROTIZING MONKEYPOX AND HIV CO-INFECTION (Monitor 9; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1050;
Diagnosed with Monkeypox and HIV three months earlier, he was on antiretroviral therapy (ART) and tecovirimat...This case illustrates how NK lymphocytopenia in HIV infection can contribute to severe, treatment-resistant Monkeypox disease. Verrucous skin lesions in an individual infected with monkeypox
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: A review of the synthetic strategies toward the antiviral drug tecovirimat. (Pubmed Central) - Sep 26, 2024
By obtaining insights from the published literature and patent records, this review elucidates the current state of knowledge regarding key synthesis parameters influencing tecovirimat production and emphasizes the critical importance of optimizing synthesis techniques to achieve remarkable improvements in safety and environmental impact. This review serves as a valuable resource for researchers and industry professionals in the field of R&D and production of APIs, particularly in expediting the safe and efficient industrial production of tecovirimat.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: Salsoline derivatives, genistein, semisynthetic derivative of kojic acid, and naringenin as inhibitors of A42R profilin-like protein of monkeypox virus: in silico studies. (Pubmed Central) - Sep 25, 2024
Monkeypox virus (MPV) infection has developed into a re-emerging disease, and despite the potential of tecovirimat and cidofovir drugs, there is currently no conclusive treatment. Moreover, the comparative free energy analyses using MM-PBSA revealed an average binding free energy of the complexes of Salsoline derivative, Genistein, Semisynthetic derivative of kojic acid, Naringenin, of -106.418, -46.808, -50.770, and -63.319
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Continuous flow synthesis of the antiviral drug tecovirimat and related sp3-rich scaffolds. (Pubmed Central) - Sep 24, 2024
Additional investigations of the key intermediate in reactions with different hydrazines revealed the accessibility of different heterocyclic chemotypes, depending on the substitution pattern of the hydrazine used. Ultimately, the streamlined and scalable access to these sp3-rich scaffolds enables improved access to tecovirimat and structurally related entities with high drug-like character.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Enrollment closed, Trial completion date, Trial primary completion date: Study to Assess the Safety and Immunogenicity of TPOXX (clinicaltrials.gov) - Sep 20, 2024
P2, N=100, Active, not recruiting,
Ultimately, the streamlined and scalable access to these sp3-rich scaffolds enables improved access to tecovirimat and structurally related entities with high drug-like character. Completed --> Active, not recruiting | Trial completion date: May 2023 --> Jul 2025 | Trial primary completion date: May 2023 --> May 2025
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein. (Pubmed Central) - Sep 12, 2024
As a result, we have shortlisted five drugs named ABX-1431, Alflutinib, Avacopan, Caspitant, and Darapalib that effectively engage the MPXV surface binding protein. Furthermore, the affinity of the proposed drugs is relatively higher than the Tecovirimat by having higher docking scores, establishing more hydrogen and hydrophobic bonds, engaging key residues in the target's structure, and exhibiting stable molecular dynamics.Communicated by Ramaswamy H. Sarma.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
OUTCOMES OF SEVERE M-POX ADMITTED TO INTENSIVE CARE UNITS AT TWO LARGE NEW YORK CITY HEALTH SYSTEMS, 2022-2024: A CASE SERIES (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5982;
However, severe manifestations of mpox in immunocompromised patients have required ICU-level care in the form of vasopressor support, intubation with mechanical ventilation, tracheostomy, and renal replacement therapy. CLINICAL IMPLICATIONS: We report one of the largest case series of mpox patients in the ICU setting, outside of nation-wide studies.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Review, Journal: Mpox treatment evolution: past milestones, present advances, and future directions. (Pubmed Central) - Sep 3, 2024
The statistical analysis revealed that tecovirimat (TCV) is the most effective antiviral drug among the other evaluated drugs, showing superior efficacy in clinical trials...The findings underscore the effectiveness of TCV in treating Mpox and highlight significant advancements in preventive treatments. The review also points to innovative approaches in vaccine technology and potential future therapies, including nanomedicine and herbal remedies, which may enhance Mpox management.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal, Real-world evidence, Real-world: Sex-based differences in treatment approaches and outcomes among patients with mpox: Limitations of real-world data. (Pubmed Central) - Aug 31, 2024
The review also points to innovative approaches in vaccine technology and potential future therapies, including nanomedicine and herbal remedies, which may enhance Mpox management. Addressing sex disparities in mpox treatment and outcomes is crucial, but existing data sources like administrative claims and clinical data repositories pose limitations.
- |||||||||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic, TPOXX (tecovirimat) / SIGA Technologies
Journal: The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges. (Pubmed Central) - Aug 20, 2024
The paper analyses different therapeutic interventions, such as tecovirimat, an antiviral medication, and JYNNEOS, a vaccine, in terms of their efficacy, potential drawbacks, and the difficulties encountered in managing outbreaks. The future outlook emphasises the ne-cessity of inventive research methodologies, worldwide monitoring, and individualised med-ical treatments to counteract the dissemination of MPXV and alleviate its consequences on public health.
- |||||||||| Cytovene (ganciclovir) / Roche, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Unveiling the Cause of GI Symptoms in a Patient With Mpox and HIV/AIDS (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1044;
Prior to admission, he completed a course of oral tecovirimat and remained compliant with Biktarvy...He was initiated on fluconazole and ganciclovir, which had to be discontinued due to worsening pancytopenia...Figure: Cutaneous lesions of Mpox (top). EGD findings suggestive of esophageal candidiasis and gastric ulcer (bottom).
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Navigating the human-monkeypox virus interactome: HuPoxNET atlas reveals functional insights. (Pubmed Central) - Aug 19, 2024
Furthermore, various protein annotations of the human and viral proteins such as gene ontology, KEGG pathways, subcellular localization, protein domains, and novel drug targets identified from our study are also available on the database. HuPoxNET is a user-friendly platform for the scientific community to gain more insights into the monkeypox disease infection and aid in the development of therapeutic drugs against the disease.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Enrollment open: EPOXI: European Trial Into Mpox Infection (clinicaltrials.gov) - Aug 12, 2024
P4, N=150, Recruiting,
HuPoxNET is a user-friendly platform for the scientific community to gain more insights into the monkeypox disease infection and aid in the development of therapeutic drugs against the disease. Not yet recruiting --> Recruiting
- |||||||||| Tembexa (brincidofovir oral) / SymBio Pharma, Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Clinical, Review, Journal: Ocular manifestations of mpox. (Pubmed Central) - Aug 8, 2024
Randomized clinical trials for mpox systemic and ocular treatment efficacy are lacking. Prior clinical experience with smallpox and in-vitro mpox data support the use of systemic antivirals such as tecovirimat, cidofovir, brincidofovir and topical use of trifluridine in ocular mpox management, though treatment-resistant infection can occur and portend a poor prognosis.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: A Severe and Prolonged Case of Ocular Monkeypox Without Systemic Manifestations. (Pubmed Central) - Aug 5, 2024
We present an unusual and challenging case of ocular mpox with severe ocular surface inflammation including peripheral corneal thinning and epithelial defects, without systemic disease. Initiation of antiviral treatment resulted in a quick resolution of the ocular disease.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Journal: Resolution of Stubborn Monkeypox With Tecovirimat in an HIV Patient. (Pubmed Central) - Jul 30, 2024
The patient was discharged on 600 mg tecovirimat orally twice daily for 14 days. At the 14-day follow-up, the patient's lesions had completely fallen off and were no longer painful.
|
